Skip to Content

Research & Funding

Past Other NCI & NIH InitiativesRSS

This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • Interdisciplinary Research Consortium (U54) Preapplication for Interdisciplinary Research Consortium (X02)

    • Release Date: April 10, 2006
    • Application Receipt Date: N/A
    • Expiration Date: N/A

    Dates: LOI: March 21, 2006; Pre-application: April 18, 2006 - Use SF-424 Electronic Submission.

    The Interdisciplinary Research Implementation Group will invite applications for Interdisciplinary Research Consortia from among those that submit a pre-application in response to PAR-06-122. This RFA with Limited Eligibility for a full consortium is released early to aid those who are writing a pre-application. Only those selected through a peer review of their pre-application are eligible to apply for a full Interdisciplinary Research Consortium. The purpose of this program is to support interdisciplinary approaches to solving significant and complex biomedical problems, particularly those that have been resistant to traditional approaches. These applications must hold the promise of leading to new research approaches to improving human health. Interdisciplinary consortia are expected to identify an important biomedically relevant problem, evaluate why previous approaches have not worked, justify why the proposed interdisciplinary approach will work, identify the methods that will keep the interdisciplinary team focused and coordinated, and propose a timeline. The review criteria will involve both the significance of the problem as well as the interdisciplinary nature of the approach to solving the problem. Applications will have to be strong in both of these areas. A successful interdisciplinary approach is defined as combining aspects of individual disciplines to provide a new conceptual approach to solving a problem that is likely to yield insights that could not have been achieved by an isolated laboratory or using a multi-disciplinary approach.

    Consortium RFA
    Pre-application
    Addendum

  • RFA-CA-06-014: Tumor Microenvironment Network (TMEN) (U54)

    • Release Date: April 10, 2006
    • Application Receipt Date: May 10, 2006
    • Expiration Date: N/A

    Letter of Intent Receipt Date: April 10, 2006
    The NCI invites cooperative agreement and NIH intramural applications from groups of investigators interested in becoming components of the NCI Tumor Microenvironment Network (TMEN). The main objective is to delineate mechanisms of tumor-stroma interactions in human cancer and to generate a comprehensive understanding of composition of the stroma in normal tissues as well as its roles in tumor initiation, progression, and metastasis.

    See full description in NIH Guide:RFA-CA-06-014

  • RFA-RM-06-007: Nanomedicine Development Centers (PN2)

    • Release Date: April 10, 2006
    • Application Receipt Date: June 23, 2006
    • Expiration Date: N/A

    Concept Approval Letter Receipt Date: March 15, 2006
    Nanomedicine is one of nine major initiatives included in the NIH Roadmap. Because Nanomedicine is an emerging biomedical discipline, the NIH engaged the biomedical research community to help define and develop concepts and a framework to stimulate work in this field. A two-year planning process, (see http://grants1.nih.gov/grants/guide/rfa-files/RFA-RM-04-018.html) culminated in the establishment of a collaborative national network of Nanomedicine Development Centers (NDC). The first four centers were awarded in fiscal year 2005. The current RFA solicits applications for additional centers that will expand the network by addressing complementary models, topics, medical targets, and approaches to the work of funded centers.

    See full description in NIH Guide: RFA-RM-06-007

    Concept Approval Letter Evaluation Information

  • PA-06-149: Innovative and Exploratory Research in Digestive Diseases and Nutrition (R21) (NIDDK, NCI, ODS)

    • Release Date: April 10, 2006
    • Application Receipt Date: March 2, 2006
    • Expiration Date: November 15, 2006

    The NIDDK and the Division of Cancer Prevention at the NCI invite applications through the exploratory/developmental (R21) grant mechanism from investigators with research interests in gastroenterology, hepatology, obesity, and nutrition and that serve the mission of NIDDK and NCI. The aim of this funding opportunity is to stimulate the application of highly novel approaches to important areas of digestive diseases (including associated cancers) and nutrition research. Areas of special interest in this funding opportunity include development of novel non invasive imaging methods to study function of the gastrointestinal tract, liver, pancreas and adipose tissue and pathogenic processes such as fibrosis, inflammation, hyperplasia, fat body accumulation.

    See full description in NIH Guide:PA-06-149

  • PAR-06-313: Cancer prevention research small grant program (R03) (NCI)

    • Release Date: April 04, 2006
    • Application Receipt Date: July 20, 2006; November 20, 2006; March 20, 2007; July 21, 2007; December 20, 2007
    • Expiration Date: December 21, 2007
    • Contacts:

      Padma Maruvada, Ph.D. (Early Detection), Phone: 301-496-3893, Email: maruvadp@mail.nih.gov

    The Division of Cancer Prevention of the NCI invites applications that address developmental research in chemoprevention agent development, biomarkers, early detection, and nutrition science. However, it is important to note that this funding opportunity does not include applications that are focused on treatment, etiology, or treatment-related quality of life studies that are population based. This Small Grants Program is designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of research expertise in cancer prevention research. It is anticipated that this Small Grant Program may lead to the submission of subsequent individual research project grants (R01).

    See full description in NIH Guide:PAR-06-313

  • PA-06-314: Pilot Studies in Pancreatic Cancer (R03) (NCI)

    • Release Date: April 04, 2006
    • Application Receipt Date: See below
    • Expiration Date: September 8, 2008 (unless reissued)
    • Contacts:

      Several NCI offices, for DCTD-Claudio Dansky Ullmann, M.D., Phone: 301-496-8866, Email: danskyullc@mail.nih.gov

    Application Submission Date(s): Standard dates apply AIDS Application Receipt Date(s): http://grants1.nih.gov/grants/funding/submissionschedule.htm#AIDS

    This funding opportunity is intended to promote innovative research across multiple disciplines for better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer.

    See full description in NIH Guide:PA-06-314

  • PAR-06-311: Imaging - science track award for research transition (I/START) (R03) (NIDA)

    • Release Date: March 31, 2006
    • Application Receipt Date: Standard dates apply
    • Expiration Date: January 3, 2009
    • Contacts:

      L R Stanford, Ph.D., Phone: 301-402-3869, Email: lstanfor@nida.nih.gov

    • Letters of Intent Receipt Date(s): 30 days prior to the application submission/receipt date

    This Funding Opportunity Announcement (FOA) issued by the NIDA is intended to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs.

    See full description in NIH Guide:PAR-06-311

  • PA-06-299: Exploratory studies in cancer detection, diagnosis, and prognosis (R21)

    • Release Date: March 30, 2006
    • Application Receipt Date: See below
    • Expiration Date: November 2, 2008
    • Contacts:

      James V. Tricoli, Ph.D., Phone: 301-496-1591, Email: tricoli@mail.nih.gov

    AIDS Application Receipt Date(s): http://grants1.nih.gov/grants/funding/submissionschedule.htm#AIDS

    The objective of this FOA is to encourage grant applications for exploratory (R21) grants from individuals who are interested in testing new ideas that may advance progress in cancer detection, diagnosis, and prognosis. Imaging studies are not intended to be funded under this initiative. For imaging initiatives, call the Cancer Imaging Program staff.

    See full description in NIH Guide:PA-06-299

  • RFA-AI-06-030: Radionuclide decorporation agents for radiation/nuclear emergencies: project bioshield (R01) (NIAID)

    • Release Date: March 30, 2006

    This is a funding opportunity announcement (FOA) to accelerate the development of safe and effective products to remove radionuclides from the body (decorporation) following nuclear contamination from any source. Specifically, candidate products will demonstrate an increase in efficiency and rate of radionuclide elimination from the body after contamination due to ingestion, inhalation or transdermal absorption.

    See full description in NIH Guide:RFA-AI-06-030

  • PA-06-295: Etiology, prevention, and treatment of hepatocellular carcinoma (R21) (NCI, NIAAA, NIBIB, NIDDK)

    • Release Date: March 29, 2006
    • Application Receipt Date: Standard dates apply
    • Expiration Date: September 8, 2008
    • Contacts:

      John Cole, Ph.D., Phone: 301-496-1718, Email: jc121b@nih.gov
      Heng Xie, M.D., M.P.H., Ph.D, Phone: 301-496-8866 or 301-496-6512, Email: XieHe@mail.nih.gov

    The several institutes are interested in receiving grant applications that address the etiology and etiologic mechanisms of hepatocellular carcinoma (HCC) and development of animal models, novel approaches to prevent this malignancy, and therapeutic or diagnostic studies aimed at establishing reliable prognostic indicators for disease progression and/or minimizing morbidity and mortality associated with this malignancy.

    See full description in NIH Guide:PA-06-295